Active ingredientPonatinibCat. No. P-P156-001CAS 943319-70-8Family · Pharmaceutical analytical standards
Ponatinib
A third-generation tyrosine kinase inhibitor for chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia, approved in the United States in December 2012. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?It was developed to hit the T315I mutation too, which makes the BCR-ABL protein resistant to other inhibitors: a slender, linear carbon-carbon triple bond lets it avoid the bulk of the mutated amino acid.
Go to the active ingredient →Active ingredientPonatinibCat. No. P-P156-001CAS 943319-70-8
Active ingredientPonatinib HydrochlorideCat. No. P-P156-002CAS 1114544-31-8
MetabolitePonatinib Metabolite AP-24567Cat. No. P-P156-003CAS 943319-87-7
MetabolitePonatinib Metabolite AP-24600Cat. No. P-P156-004CAS 1300690-48-5
MetabolitePonatinib N-beta-D-GlucuronideCat. No. P-P156-005
Isotopically labelledPonatinib-d8Cat. No. P-P156-006CAS 1562993-37-6
NitrosamineN-Nitroso Ponatinib Metabolite AP-24567Cat. No. P-P156-007
ImpurityPonatinib Impurity 1Cat. No. P-P156-008
ImpurityPonatinib Impurity 2Cat. No. P-P156-009CAS 694499-26-8
ImpurityPonatinib Impurity 3Cat. No. P-P156-010CAS 1356385-96-0
ImpurityMethyl 3-ethynyl-4-methylbenzoateCat. No. P-P156-011CAS 1255099-13-8
ImpurityPonatinib Impurity 4Cat. No. P-P156-012
ImpurityPonatinib Impurity 5Cat. No. P-P156-013CAS 2097674-16-1
ImpurityPonatinib Impurity 6Cat. No. P-P156-014
ImpurityPonatinib N-OxideCat. No. P-P156-015CAS 2227480-51-3No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.